CORESTEMCHEMON Inc., a bio-pharmaceutical company, engages in the development and production of stem cell therapies for the treatment of incurable diseases in South Korea. It offers NEURONATA-R inj, an autologous bone marrow mesenchymal stem cell therapy for the treatment of amyotrophic lateral sclerosis (ALS). The company also engages in the development of various therapy products for the treatment of systemic lupus erythematosus (SLE), multiple system atrophy (MSA), and cerebellar ataxia (CA) diseases. The company has a strategic partnership with ATG Lifetech to deliver precision-driven non-clinical solutions to pharmaceutical companies and biotech ventures. The company was formerly known as Corestem, Inc. CORESTEMCHEMON Inc. was founded in 2003 and is based in Seongnam-si, South Korea.
Metrics to compare | 166480 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship166480PeersSector | |
---|---|---|---|---|
P/E Ratio | −4.1x | −5.3x | −0.5x | |
PEG Ratio | −0.09 | −0.10 | 0.00 | |
Price/Book | 1.4x | 2.5x | 2.6x | |
Price / LTM Sales | 2.6x | 5.7x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 45.1% | |
Fair Value Upside | Unlock | 17.4% | 7.4% | Unlock |